NKTX Nkarta

Nkarta Announces February and March 2021 Investor Conference Schedule

Nkarta Announces February and March 2021 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

SVB Leerink 10th Annual Global Healthcare Conference

February 26, 2021

Fireside chat presentation: 1:40 p.m. ET



Cowen 41st Annual Health Care Conference

March 3-4, 2021

No presentation



Barclays Global Healthcare Conference

March 11, 2021

Fireside chat presentation: 10:20 a.m. ET

Live audio webcasts of the presentations will be available on the Investors section of Nkarta’s website, . Replays of the webcasts will be archived on the website for approximately four weeks.

About Nkarta

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at .

Nkarta Media/Investor Contact:

Greg Mann

Nkarta, Inc.



EN
17/02/2021

Underlying

NKTXNkarta

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nkarta

 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoi...

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis cohort to be added to Ntrust-2Dosing continues at 4 billion cell dose level (12 billion cells in 3-dose cycle) with initial data expected to be presented at a medical meeting this year SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage bio...

April 15, 2026 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta to Participate in Needham Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference. At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, “Cell Therapy in Autoimmune: State of the Art and What Comes Next.” Later that afternoon, Nkarta Pres...

April 9, 2026 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and...

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026Cash balance of $295.1 million on December 31, 2025, including cash, cash equivalents and investments, is expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology com...

March 25, 2026 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in March Investor Conferences

Nkarta to Participate in March Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: March 2, 2026TD Cowen 46th Annual Health Care ConferenceBoston, MA9:10 a.m. EST – fireside chatMarch 10, 2026Leerink Global Healthcare ConferenceMiami, FL10:40 a.m. EDT – fireside chatA simultaneous webcast of both events will be available on the ...

February 27, 2026 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.47
STZ Constellation B...
OXY Occidental Petr... ... (+41)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

STZ CONSTELLATION BRANDS INC. CLASS A
OXY OCCIDENTAL PETROLEUM CORPORATION
AMN AMN HEALTHCARE SERVICES INC.
PPC PILGRIM'S PRIDE CORPORATION
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
LAND GLADSTONE LAND CORP.
JCOM J2 GLOBAL INC.
JACK JACK IN THE BOX INC.
IPAR INTER PARFUMS INC.
INGR INGREDION INCORPORATED
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
EXPO EXPONENT INC.
EPC EDGEWELL PERSONAL CARE CO.
EMN EASTMAN CHEMICAL COMPANY
CLX CLOROX COMPANY
CE CELANESE CORPORATION
ACCO ACCO BRANDS CORPORATION
HRI HERC HOLDINGS INC.
OFLX OMEGA FLEX
WDFC WD-40 COMPANY
BOOM DMC GLOBAL INC
UAA UNDER ARMOUR INC. CLASS A
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
FNKO FUNKO CLASS A
SPB SPECTRUM BRANDS HOLDINGS INC.
AVNS AVANOS MEDICAL INC.
DOW DOW INC.
AMCR AMCOR PLC
ATEX ANTERIX INC
BJ BJ'S WHOLESALE CLUB HOLDINGS
NVAX NOVAVAX INC.
VIR VIR BIOTECHNOLOGY
ALT ALTIMMUNE INC
NKTX NKARTA
PTLO PORTILLOS INC
CHRD CHORD ENERGY CORPORATION
LIN LINDE PUBLIC LIMITED COMPANY
HUN GLOBAL X NATURAL GAS ETF
INR INFINITY NATURAL RESOURCES INC
MUSA MIDDLEFIELD US EQUITY DIV ET ETF UN
01/28/26 January 28, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch